耳鼻喉科Pubmed文献追踪每日 14:00 同步
← 返回全部文献
Article record

智利成人慢性鼻窦炎伴鼻息肉局部与全身性糖皮质激素使用调查

Survey of Local and Systemic Corticosteroids Use in Adults with Chronic Rhinosinusitis with Nasal Polyps in Chile.

临床研究鼻科IF 5.1Q2

文献信息

PMID42801241
原文在 PubMed 查看原文 ↗
发表日期2026
作者Diego Navarro-Aguilar
查看其他 11 位作者

Constanza J Valdés；German Seguí；Cristian Daszenies；Erich Niklitschek；Gerardo Oberreuter；Alex S León；María Jesús Rojas-Lechuga；Ramón Moreno-Luna；Davide Stivalini；Valeria Gambacorta；Eugenio De Corso

作者单位ENT Department, Hospital Base de Valdivia, Los Rios, Valdivia, Chile.
查看其他 8 条单位信息

Faculty of Medicine, Universidad San Sebastián, Los Rios, Valdivia, Chile.；ENT Department, Hospital del Salvador, Universidad de Chile, Santiago, Chile.；ENT Department, Clinica Las Condes, Santiago, Chile.；Faculty of Medicine, Universidad Austral de Chile, Los Rios, Valdivia, Chile.；Rhinology and Skull Base Unit, ENT Department, Hospital Clinic, Barcelona, Spain.；Rhinology and Skull Base Unit, ENT Department, Hospital Universitario Virgen Macarena, Seville, Spain.；Department of Medicine and Surgery, Section of Otorhinolaryngology, Santa Maria Della Misericordia's Hospital, Perugia, Italy.；ENT Department, Otorhinolaryngology Unit, Head and Neck Department, Fondazione Policlinico Universitario A, Gemelli Hospital IRCCS, Rome, 00168, Italy.

期刊Journal of inflammation research
SCI 分区Q2
IF5.1
研究类型临床研究 · 临床
所属专科鼻科

中文摘要

引言： 局部和全身性糖皮质激素长期以来一直是慢性鼻窦炎伴鼻息肉（CRSwNP）治疗的主要手段，尽管尚无普遍接受的处方模式。在智利进行了一项调查，以确定成人CRSwNP患者中局部和全身性糖皮质激素的当前处方情况。
目的： 描述智利耳鼻喉科医生为成人CRSwNP患者开具的局部和全身性糖皮质激素使用情况。
材料与方法： 一项横断面研究。对智利耳鼻咽喉科学会活跃成员进行了一项自填式在线调查，共有104名专业人员参与。
结果： 在CRSwNP中，最常开具的局部糖皮质激素是莫米松（69.2%），剂型为每日鼻喷剂。鼻腔冲洗常被指示作为辅助治疗。大多数受访者认为局部类固醇的局部不良反应轻微，全身不良反应不常见。泼尼松是最常用的全身性糖皮质激素（86.5%），尤其是在急性加重期短期使用。然而，在疗程、剂量和给药途径方面存在异质性。在手术中，全身性糖皮质激素用于优化结果并减少并发症。
结论： 慢性鼻窦炎伴鼻息肉的治疗结合了药物和手术方法。根据多项国际指南，局部糖皮质激素是必不可少的。全身性糖皮质激素的使用应合理，评估风险与获益。鉴于本研究中关于类固醇处方的结果存在异质性，应考虑制定临床指南以规范智利局部和全身性糖皮质激素的合理使用。

英文摘要

INTRODUCTION: Local and systemic corticosteroids have long been the mainstay in the treatment of chronic rhinosinusitis with nasal polyps (CRSwNP), although there is no universally accepted prescription modality. A survey was conducted in Chile to determine the current prescription of topical and systemic corticosteroids in adult patients with CRSwNP.
OBJECTIVE: To describe the use of local and systemic corticosteroids in adult patients with CRSwNP prescribed by otolaryngologists in Chile.
MATERIAL AND METHOD: A cross-sectional study. A self-administered online survey was conducted among active members of the Chilean Society of Otorhinolaryngology, with 104 participating professionals.
RESULTS: In CRSwNP, the most frequently prescribed topical corticosteroid was mometasone (69.2%) in the form of a daily intranasal spray. Nasal lavage is frequently indicated as an adjunctive treatment. The majority of respondents considered local adverse effects of local steroids to be minimal and systemic adverse effects to be infrequent. Prednisone is the most commonly used systemic corticosteroid (86.5%), especially in short bursts during exacerbations. However, there is heterogeneity in duration, dose, and route of administration. In surgery, systemic corticosteroids are used to optimize outcomes and reduce complications.
CONCLUSION: The treatment of chronic rhinosinusitis with nasal polyps combines a medical and surgical approach. Topical corticosteroids are essential according to multiple international guidelines. The use of systemic corticosteroids should be rational, assessing risks and benefits. Given the heterogeneity of the results obtained in this study regarding steroid prescription, the development of clinical guidelines to standardize the rational use of topical and systemic corticosteroids in Chile should be considered.